Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: Randomised phase 1b trial

The Lancet Haematology

Volumn 3, Issue 2, 2016, Pages e87-e98

  Nakamura, Ryotaro ^a   Rosa, Corinna La ^a   Longmate, Jeffrey ^a   Drake, Jennifer ^a   Slape, Cynthia ^a   Zhou, Qiao ^a   Lampa, Melanie G ^a   O'Donnell, Margaret ^a   Cai, Ji Lian ^a   Farol, Len ^a   Salhotra, Amandeep ^a   Snyder, David S ^a   Aldoss, Ibrahim ^a   Forman, Stephen J ^a   Miller, Jeffrey S ^b   Zaia, John A ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS VACCINE; DOUBLE STRANDED DNA ANTIBODY; ETOPOSIDE; FLUDARABINE; IMMUNOLOGICAL ADJUVANT; MELPHALAN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; AGATOLIMOD; EPITOPE; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 9; VIRUS VACCINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; INFECTION; KARNOFSKY PERFORMANCE STATUS; LIMIT OF DETECTION; MACULOPAPULAR RASH; MALE; MORTALITY; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; VIREMIA; VIRUS GENOME; AGED; AGONISTS; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL VACCINES; VIREMIA; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84957935609     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00246-X     Document Type: Article

References (36)

1. Bosch M, Khan FM, Storek J Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012, 19:324-335.
2. Ljungman P, Hakki M, Boeckh M Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011, 25:151-169.
3. Ramanathan M, Teira P, Battiwalla M, et al. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis. Blood 2014, 124(suppl). abstr 47.
4. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1687-1699.
5. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009, 49:1851-1860.
6. Stemberger C, Graef P, Odendahl M, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014, 124:628-637.
7. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
8. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-685.
9. Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med 2015, 7:285ra63.
10. Chalandon Y, Degermann S, Villard J, et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006, 107:389-396.
11. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009, 44:453-455.
12. Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010, 116:1655-1662.
13. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
14. Kharfan-Dabaja MA, Nishihori T Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines 2015, 14:341-350.
15. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205:1294-1304.
16. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
17. Nakamura R, Palmer JM, O'Donnell MR, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leukemia Res 2012, 36:1152-1156.
18. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997, 90:1751-1767.
19. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27:460-471.
20. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
21. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131-1139.
22. Suessmuth Y, Mukherjee R, Watkins B, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire. Blood 2015, 125:3835-3850.
23. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
24. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991, 164:483-487.
25. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
26. Cobelens FG, Egwaga SM, Van Ginkel T, et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006, 43:634-639.
27. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
28. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001, 52:165-173.
29. Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015, 519:366-369.
30. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002, 100:3690-3697.
31. La Rosa C, Wang Z, Brewer JC, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002, 100:3681-3689.
32. Lacey SF, Gallez-Hawkins G, Crooks M, et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002, 74:722-732.
33. La Rosa C, Wang Z, Lacey SF, et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 2006, 34:497-507.
34. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005, 23:7199-7206.
35. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013, 122:1316-1324.
36. Foley B, Cooley S, Verneris MR, et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C+ NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 2012, 189:5082-5108.